← Gordon B. Mills

Papers by Gordon B. Mills

Page 4 · newest first

151. Characterization of anticancer drug resistance by reverse-phase protein array: new targets and strategiesExpert Review of Proteomics · 2022
152. Whole-chromosome arm acquired uniparental disomy in cancer development is a consequence of isochromosome formationNeoplasia · 2022
153. Ovarian cancer recurrence: “is the definition of platinum resistance modified by PARP inhibitors and other intervening treatments?”Cancer Drug Resistance · 2022
154. Profiling of immune features to predict immunotherapy efficacyThe Innovation · 2021
155. Costimulation of γδTCR and TLR7/8 promotes Vδ2 T-cell antitumor activity by modulating mTOR pathway and APC functionJournal for ImmunoTherapy of Cancer · 2021
156. WEE1 inhibition induces anti-tumor immunity by activating ERV and the dsRNA pathwayThe Journal of Experimental Medicine · 2021
157. Multiomics analysis of serial PARP inhibitor treated metastatic TNBC inform on rational combination therapiesnpj Precision Oncology · 2021
158. Systematic discovery of mutation-directed neo-protein-protein interactions in cancer2021
159. Interleukin enhancer‐binding factor 2 promotes cell proliferation and DNA damage response in metastatic melanomaClinical and Translational Medicine · 2021
160. A Modified Nucleoside 6-Thio-2′-Deoxyguanosine Exhibits Antitumor Activity in GliomasClinical Cancer Research · 2021
161. Caveolin-1 and Sox-2 are predictive biomarkers of cetuximab response in head and neck cancerJCI Insight · 2021
162. Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian CancerClinical Cancer Research · 2021
163. Multiplex spatial systems analysis of local nanodose drug responses predicts effective treatment combinations of immunotherapies and targeted agents in mammary carcinoma2021
164. CCNE1 copy number is a biomarker for response to combination WEE1-ATR inhibition in ovarian and endometrial cancer modelsCell Reports Medicine · 2021
165. Neural Crest-Like Stem Cell Transcriptome Analysis Identifies LPAR1 in Melanoma Progression and Therapy ResistanceCancer Research · 2021
166. PU.1 and MYC transcriptional network defines synergistic drug responses to KIT and LSD1 inhibition in acute myeloid leukemia2021
167. A LINCS microenvironment perturbation resource for integrative assessment of ligand-mediated molecular and phenotypic responses2021
168. Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanomaOncogene · 2021
169. Relevance of circulating hybrid cells as a non-invasive biomarker for myriad solid tumorsScientific Reports · 2021
170. In Situ Tumor Vaccination with Nanoparticle Co‐Delivering CpG and STAT3 siRNA to Effectively Induce Whole‐Body Antitumor Immune ResponseAdvanced Materials · 2021
171. Mechanical stress in pancreatic cancer: Signaling pathway adaptation activates cytoskeletal remodeling and enhances cell migration2021
172. Phase 1 trial of nelfinavir added to standard cisplatin chemotherapy with concurrent pelvic radiation for locally advanced cervical cancerCancer · 2021
173. ME-VAE: Multi-Encoder Variational AutoEncoder for Controlling Multiple Transformational Features in Single Cell Image Analysis2021
174. Spatially interacting phosphorylation sites and mutations in cancerNature Communications · 2021
175. Targeting Adaptation to Cancer Treatment by Drug Combinations2021
176. Selective abrogation of S6K2 maps lipid homeostasis as a survival vulnerability in MAPKi-resistant NRAS MUT melanoma2021
177. Landscapes of cellular phenotypic diversity in breast cancer xenografts and their impact on drug responseNature Communications · 2021
178. Genomic, Transcriptomic, and Proteomic Profiling of Metastatic Breast CancerClinical Cancer Research · 2021
179. Characterizing advanced breast cancer heterogeneity and treatment resistance through serial biopsies and comprehensive analyticsnpj Precision Oncology · 2021
180. Relevance of Circulating Hybrid Cells as a Non-Invasive Biomarker for Myriad Solid Tumors2021
181. Association Between Sex and Immune-Related Adverse Events During Immune Checkpoint Inhibitor TherapyJNCI Journal of the National Cancer Institute · 2021
182. Frequent post-operative monitoring of colorectal cancer using individualised ctDNA validated by multiregional molecular profilingBritish Journal of Cancer · 2021
183. MEK Inhibition Remodels the Immune Landscape of Mutant KRAS Tumors to Overcome Resistance to PARP and Immune Checkpoint InhibitorsCancer Research · 2021
184. Spatially Interacting Phosphorylation Sites and Mutations in Cancer2021
185. Protein Signature Predicts Response to Neoadjuvant Treatment With Chemotherapy and Bevacizumab in HER2-Negative Breast CancersJCO Precision Oncology · 2021
186. Modeling Heterogeneity of Triple‐Negative Breast Cancer Uncovers a Novel Combinatorial Treatment Overcoming Primary Drug ResistanceAdvanced Science · 2020
187. Scanning thermal microscopy on samples of varying effective thermal conductivities and identical flat surfacesJournal of Applied Physics · 2020
188. Ex Vivo Analysis of Primary Tumor Specimens for Evaluation of Cancer TherapeuticsAnnual Review of Cancer Biology · 2020
189. Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancerBreast Cancer Research · 2020
190. Peritoneal Spread of Ovarian Cancer Harbors Therapeutic Vulnerabilities Regulated by FOXM1 and EGFR/ERBB2 SignalingCancer Research · 2020
191. Inhibition of the ATM/Chk2 axis promotes cGAS/STING signaling in ARID1A-deficient tumorsJournal of Clinical Investigation · 2020
192. Proteomic analysis of circulating extracellular vesicles identifies potential markers of breast cancer progression, recurrence, and responseScience Advances · 2020
193. Multi-omics prediction of immune-related adverse events during checkpoint immunotherapyNature Communications · 2020
194. Synthetic lethal combination targeting BET uncovered intrinsic susceptibility of TNBC to ferroptosisScience Advances · 2020
195. Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant MelanomaClinical Cancer Research · 2020
196. The roles of MAGEA6 variants in pancreatic cancer development and their potential impact on cancer immunotherapyAutophagy · 2020
197. Analysis of Ugandan cervical carcinomas identifies human papillomavirus clade–specific epigenome and transcriptome landscapesNature Genetics · 2020
198. Multi-omics analysis of serial samples from metastatic TNBC patients on PARP inhibitor monotherapy provide insight into rational PARP inhibitor therapy combinations2020
199. Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer modelsNature Communications · 2020
200. Candidate biomarker assessment for pharmacological responseTranslational Oncology · 2020